Intro
In 2025, the alliance of leading CDMO companies gave rise to The Healthea Group, a new European industrial player. Backed by over 40 years of expertise, the Group is ready to support clients with comprehensive, end-to-end services.
With five manufacturing facilities spanning a total area of 26,000 m², the companies within the Group produce all pharmaceutical forms across categories such as medical devices, cosmetics, food supplements, and foods for special medical purposes.
Two R&D laboratories, one accredited microbiological laboratory, a portfolio of ready-to-market products—including patent-pending formulations under clinical trials—and over 30 medical devices across 14 therapeutic areas complete the service offering that defines The Healthea Group.
The group’s current companies, which continue to grow, include: BIODUE, FARCODERMA, and HEALTHEA LICENSING. Many opportunities and challenges lie ahead for The Healthea Group, along with the ambitious goals set by those leading its formation, as reflected in their own words.
Davide Masini, Group CEO
Q: What is the Group’s long-term vision for consolidating and expanding its position in the CDMO healthcare sector?
A: We aim to strengthen our leadership in contract manufacturing by offering increasingly innovative, flexible, and sustainable solutions. Our strategy is based on three key pillars:
– Investment in technology to enhance production efficiency and ensure high quality standards.
– International expansion and market presence, especially in high-growth strategic regions.
– Sustainability across our production chain, adopting greener processes and continuously reducing waste.
Q: How do you see the healthcare market evolving in the next 5–10 years?
A: We anticipate greater product personalization, growth in digital health, and a stronger focus on sustainability. The ability to adapt swiftly will be crucial to our success.
Q: How is The Healthea Group staying competitive and innovative in such a dynamic market?
A: We are increasing our investments in R&D, innovating production processes, and establishing strategic partnerships with startups and research centers. Innovation is vital to maintaining our leadership. Key directions include:
– Automation and digitalization to enhance plant efficiency.
– Waste reduction.
– Ongoing development of advanced formulations, including sustained and targeted-release functional supplements.
Andrea Maggioni, Group CCO
Q: What strategies are you adopting to attract new clients and retain existing ones in a competitive market?
A: We offer a full CDMO service, including regulatory support, formulation development, and innovative packaging. We also focus heavily on white-label product development, providing turnkey solutions for brands aiming to rapidly launch new products while cutting R&D time and costs.
Our recent acquisition of a business unit from BMG Pharma, adding 15 medical devices in the oral-care and dermatology fields, significantly strengthens our position in Europe.
Q: Are you seeing changes in consumer behavior or product preferences in the health sector? How is the Group adapting?
A: Consumers increasingly seek personalized, sustainable products with a focus on prevention. As a result, we are expanding our offerings in categories like functional cosmetics and medical devices.
Q: How do you address competition, especially as innovation becomes a key differentiator in the health industry?
A: The health market is increasingly dynamic, with new startups introducing innovative, digital-first business models. To maintain and grow our competitive edge, we strengthen our core competencies—such as product and production versatility and our ready-to-market portfolio.
We differentiate through:
– A broad and diverse commercial offering.
– Strategic acquisitions.
– Ongoing innovation.
We are also optimizing our supply chain to ensure record-speed delivery of ready-to-market solutions. This combination enables us to compete effectively with emerging players and reinforce our leadership position.
Giulia Nannoni, Group CDO
Q: How does the Group manage regulatory and certification challenges for new products?
A: We have an internal team dedicated to regulatory monitoring and we collaborate with certifying bodies to ensure compliance with high-quality standards. Our R&D and Regulatory departments work together from the earliest development stages, integrating compliance into the innovation process and accelerating time-to-market.
Q: Are there strategic partnerships in place to accelerate innovation?
A: We partner with universities, startups, and research centers to develop new technologies and enhance product performance. These collaborations also support the execution of preclinical and clinical efficacy and safety studies on our formulations. Through these synergies, we gain faster access to scientific discoveries and translate them into innovative products.
Q: Which emerging technologies are likely to reshape R&D in the coming years, and how is the Group preparing?
A: We are investing in artificial intelligence and innovative delivery systems, such as CAPS IN CAPS, which offers advanced active ingredient release. Several formulations using this technology are patent-pending and currently undergoing clinical evaluation.
Giorgio Terzino, Group CTO
Q: With increasing digitalization and technological innovation, which key technologies is The Healthea Group implementing to enhance production and development?
A: We are upgrading our ERP systems to optimize the traceability and quality of our production and supply chain. Recently, we launched CAPS IN CAPS technology, which allows for combining typically incompatible products within a single dose, enabling us to deliver groundbreaking formulations.
Q: Are modern technologies like automation and AI impacting efficiency and quality in health product manufacturing?
A: Automation and AI are boosting efficiency by reducing production time and increasing accuracy in dosing and packaging. Our main initiatives include:
– Advanced automation of production lines, which shortens production cycles and improves precision.
– Minimizing waste, leading to more sustainable and cost-effective processes.
